Published in Blood Weekly, August 8th, 2002
"Based on the antitumor activity that Revimid has demonstrated in preclinical and clinical studies, we believe it has significant potential in treating hematological...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.